Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rucaparib Maintenance Therapy in Advanced Cervical Cancer (MaRuC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03795272
Recruitment Status : Not yet recruiting
First Posted : January 7, 2019
Last Update Posted : September 6, 2019
Sponsor:
Collaborators:
Institute of Cancer Research, United Kingdom
Central and Eastern European Oncology Group
North Eastern Germany Society of Gynaecologic Oncology
Belgian Gynaecological Oncology Group
Princess Margaret Hospital, Canada
PGOG (Polish Gynaecologic Oncology Group)
GSO Global Clinical Research BV
GCP-enhederne
Information provided by (Responsible Party):
Nordic Society for Gynaecologic Oncology

Brief Summary:
To evaluate the efficacy of PARP inhibitor, rucaparib as maintenance therapy for locally advanced cervical cancer

Condition or disease Intervention/treatment Phase
Cervical Cancer Drug: Rucaparib Drug: Placebo Phase 2

Detailed Description:

The use of concomitant cisplatin-based chemo-radiation for cervical cancer has improved survival of locally advanced cervical cancer patients and has become the standard of care. A meta-analysis revealed that the addition of concurrent chemotherapy to radiation increased the 5-year overall survival rate by 6% (HR 0.81: 60 vs 66%), and 5-year disease-free survival rate by 8%, though there is still considerable need for improvement as most patients who relapse are incurable. The unmet need is particularly higher in patients that are at high risk of recurrence. The main negative prognostic factors are higher FIGO stage as well as the presence of positive lymph nodes. Current studies are evaluating role of adjuvant chemotherapy following chemo-radiation in locally advanced disease and will possibly improve survival by reducing risk of distant metastases, however at the cost of excessive toxicity.

PARP inhibitors have shown considerable clinical benefit especially in platinum-sensitive relapsed ovarian cancer. Several PARP inhibitors have been evaluated in other gynaecological malignancies and three PARP inhibitors (olaparib, rucaparib & niraparib) are approved by European Medicines Agency and Food & Drug Administration for treatment or as maintenance therapy in ovarian cancer. Human papillomavirus causes oxidative stress that may result in DNA single-strand breaks. In cervical cancer PARP-1 expression/activity may be up-regulated in response to the ongoing oxidative stress (HPV and inflammation), and this may promote progression. This may create a vicious circle of inflammation, PARP activation, NAD+ consumption, adenosine triphosphate consumption, necrosis, and inflammation. PARPi may limit the role of PARP-1 in promoting inflammation and oxidative stress. There is theoretical plausibility that PARPi may have a role in the treatment of cervical carcinoma.

This phase II randomized placebo-controlled double-blind study will evaluate the efficacy and safety of rucaparib as adjuvant treatment for patients with locally advanced cervical cancer who are responding to chemo-radiation. This investigator-initiated study will be performed within the GCIG/ENGOT collaboration


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 162 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a multicentre, phase 2, double-blind, placebo-controlled trial of maintenance rucaparib to obtain evidence of clinical benefit of rucaparib in locally advanced cervical cancer.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: double-blinded placebo-controlled
Primary Purpose: Treatment
Official Title: A Randomized Double-blind Placebo-controlled Phase II Trial of Rucaparib Maintenance Therapy for Patients With Locally Advanced Cervical Cancer.
Estimated Study Start Date : November 1, 2019
Estimated Primary Completion Date : November 1, 2022
Estimated Study Completion Date : November 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer
Drug Information available for: Rucaparib

Arm Intervention/treatment
Experimental: Rucaparib
Patients will be treated with active oral drug, Rucaparib twice daily for 24 months
Drug: Rucaparib
2:1 randomization to receive rucaparib/placebo twice daily for 24 month
Other Name: active maintenance

Placebo Comparator: Placebo
Patients will be treated with oral placebo twice daily for 24 months
Drug: Placebo
placebo
Other Name: matched placebo maintenance




Primary Outcome Measures :
  1. Progression-Free Survival in months [ Time Frame: 42 months ]
    the time from randomization until the date of the first objective radiological disease progression according to investigator assessment of RECIST v1.1 or death by any cause, whichever occurs first.


Secondary Outcome Measures :
  1. Progression Free Survival in Sub-Population in months [ Time Frame: 42 months ]
    the time from randomization until the date of the first objective radiological disease progression according to investigator assessment of RECIST v1.1 or death by any cause, whichever occurs first for the predefined study subgroups.

  2. Patient Reported Outcomes [ Time Frame: 42 months ]
    Quality of Life Questionnaire

  3. Overall Survival in months [ Time Frame: 60 months ]
    the time from randomization until the date of death by any cause



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed squamous cell, adenocarcinoma or adenosquamous carcinoma of the cervix.
  2. Patient must have completed definitive chemoradiation and is evaluated to be in complete remission 10-12 week's post definitive treatment.
  3. Initial FIGO stage IIB with positive nodes (histological verification or verified by MRI/PET-CT), FIGO stages IIIA, IIIB, IVA; or any stage with para-aortic metastases (including IB and IIA with positive aortic nodes).
  4. Toxicities resulting from definitive treatment must resolve to grade ≤1 prior to randomization.
  5. Patient must consent that archival tumour tissue can be collected at the time of screening and used for translational studies.
  6. Patient must consent to collection of whole blood and blood plasma during the study period. These samples will be stored and later used for translational studies.
  7. Patient agrees to undergo all analysis; radiological examinations according to protocol.
  8. The patient agrees to complete PROs (QoL questionnaire) during study treatment.
  9. Patients must give informed consent.
  10. Patients must be at least 18 years of age.
  11. ECOG performance status 0-1
  12. Serum albumin >30g/l.
  13. Adequate organ function

    • Absolute neutrophil count (ANC) ≥1,500/mcL
    • Platelets >100,000/mcL
    • Haemoglobin ≥ 9g/dl (no blood transfusions for 4 weeks prior entering the trial.)
    • Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥50mL/min using Cockcroft-Gault formula.
    • Total bilirubin ≤1.5x ULN.
    • Alanine aminotransferase (ALT) ≤2.5x ULN
  14. Life expectancy of at least 12 weeks.
  15. Women of childbearing potential must use highly effective methods of birth control for the duration of study participation and for 6 months afterwards.
  16. All patients: Patients should not donate blood or blood components while participating in this study and through 90 days after receipt of the final dose of IMP. -

Exclusion Criteria:

  1. Histological types other than in inclusion criteria, like sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial cancers.
  2. Concurrent cancer therapies or cancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, biologic or hormonal therapy) within last 4 weeks.
  3. Concurrent treatment with an investigational agent or participation in another clinical trial.
  4. Previous malignant disease: patients are not eligible for the study if actively being treated of invasive cancer. Patients with previous malignant disease who are relapse-free and treatment-free for more than three years may enter this study. Patients with previous history of in-situ carcinoma of cervix, or non-invasive basal cell and squamous cell skin carcinoma can enter this trial.
  5. Active infections or other serious underlying significant medical illness, abnormal laboratory finding or psychiatric illness/social situation that would, in the investigator's judgment, make the patient inappropriate for this study. Known active or chronic hepatitis C and/or B infection. Has known history of tuberculosis.
  6. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug.
  7. Any evidence of distant metastases.
  8. Significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months prior to randomization, congestive heart failure >NYHA II (New York Heart Association), severe peripheral vascular disease, clinically significant pericardial effusion.
  9. Pregnancy or breastfeeding. Patients with preserved reproductive capacity, unwilling to use a medically acceptable method of contraception for the duration of the trial and for 6 months afterwards.
  10. Known hypersensitivity to the trial drugs, or to their excipients.
  11. Persons who have been committed to an institution by official or judicial order
  12. Patients with dependency on the sponsor, investigator or study site -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03795272


Contacts
Layout table for location contacts
Contact: Mansoor R Mirza, MD +4535453311 mansoor@rh.regionh.dk

Locations
Layout table for location information
Denmark
Rigshospitalet
Copenhagen, Sjaelland, Denmark, 2100
Rigshospitalet Not yet recruiting
København Ø, Sjaelland, Denmark, 2100
Contact: Kirsten Pors, RN    +45353311    kirsten.pors@regionh.dk   
Contact: MANSOOR RAZA MIRZA, MD    +4535459624    mansoor@rh.regionh.dk   
Sponsors and Collaborators
Nordic Society for Gynaecologic Oncology
Institute of Cancer Research, United Kingdom
Central and Eastern European Oncology Group
North Eastern Germany Society of Gynaecologic Oncology
Belgian Gynaecological Oncology Group
Princess Margaret Hospital, Canada
PGOG (Polish Gynaecologic Oncology Group)
GSO Global Clinical Research BV
GCP-enhederne

Layout table for additonal information
Responsible Party: Nordic Society for Gynaecologic Oncology
ClinicalTrials.gov Identifier: NCT03795272     History of Changes
Other Study ID Numbers: ENGOT-Cx7-NSGO/MaRuC
First Posted: January 7, 2019    Key Record Dates
Last Update Posted: September 6, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nordic Society for Gynaecologic Oncology:
Cervical cancer
rucaparib
maintenance therapy
placebo-controlled
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Rucaparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents